Found 1 Presentation For Request "998P"
998P - The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients
- Cheng Wei (hunan, China)
Abstract
Background
The approval of ICIs for HCC has changed the treatment landscape of HCC, which is the fourth most common and the second lethal malignancy in China. But ICIs have also been linked to the possibility of accelerating disease progression. Previous reports have indicated
Methods
Targeted deep sequencing with 450 cancer-associated genes was performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissues and matching blood samples that collected from a cohort of 1292 Chinese HCC patients. The HP-related genomic alterations such as
Results
A total of 1292 HCC patients (male=1121, female=171) was included in this study, of which 202 (15.6%) patients presented HP-related gene alterations. Among them,
Conclusions
To our knowledge, this was the largest cohort studying the mutational landscape of biomarkers associated with HP in response to ICIs in Chinese HCC patients. The high incidence of 11q13 amplification and
Legal entity responsible for the study
Hunan Provincial People's Hospital.
Funding
Has not received any funding.
Disclosure
H. Qing, Y. Shaohua, W. Weifeng: Full/Part-time employment: OrigiMed. All other authors have declared no conflicts of interest.